Abstract
Inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn’s disease (CD), are chronic intestinal diseases of unknown etiology that present with variable disease extents and outcomes. The use of biomarkers for the diagnosis and management of IBDs is considered beneficial. Palmitoleic acid (PO) is an adipose tissue-derived mono-unsaturated free fatty acid that potentially serves as a lipokine in metabolic and inflammatory diseases. The aim of this study was to investigate the significance of PO levels in the serum of patients with UC and CD. The study included patients with UC (n = 22), patients with CD (n = 35), and controls (n = 22). The levels of serum PO were analyzed using gas chromatography. The association of serum PO levels with the clinical features and disease outcomes in IBD was examined. Serum PO levels were significantly higher in patients with CD than in controls, whereas no difference in these levels was observed between patients with UC and controls. Serum PO levels were significantly associated with the CD activity index. Additionally, high serum PO levels were associated with an increased risk of surgical intervention requirement during follow-up. In a pilot study with a few patients, high PO levels were observed in the mesenteric tissue in the active disease site of patients with CD (n = 7) compared with those with colon cancer (n = 6). Elevated serum PO levels might serve as a marker for local inflammation and prognosis in patients with CD.
Highlights
Inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn’s disease (CD), are chronic intestinal diseases of unknown etiology that present with variable disease extents and outcomes
We found serum Palmitoleic acid (PO) levels to be significantly higher in patients with CD than in healthy controls; serum PO levels were positively correlated with disease activity in patients with CD but were not correlated with body mass index (BMI) or elemental diet, which are the possible factors besides disease activity that can affect PO levels
Elevated serum PO levels were associated with an increased risk of requiring surgical intervention
Summary
Inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn’s disease (CD), are chronic intestinal diseases of unknown etiology that present with variable disease extents and outcomes. Ulcerative colitis (UC) and Crohn’s disease (CD) are inflammatory bowel diseases (IBDs) They exhibit similar clinical manifestations; only the mucosal layer in the large intestine is affected in U C1, whereas the entire gastrointestinal system may be involved in C D1. Both diseases often require long-term treatments, including 5-aminosalicylic acid (5-ASA), immune-suppressor, and anti-tumor necrosis factor-alpha (TNF-α) administration. The activation of adipocytes releases subsets of fat-derived hormones, such as vaspin and adiponectin These hormones influence gastrointestinal immune responses by modulating the expression of proinflammatory interleukins and adhesion factors, especially, TNF-α, which plays a crucial role in the pathogenesis of IBD5. No Sex Male Female Age (range; in years) BMI (range; in kg/m2) CDAI ≥ 150 < 150 CAI ≥ 6 < 6 Current treatment 5-ASA Steroid Azathioprine Infliximab GCAP/LCAP Tacrolimus Elemental diet
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
